PL2422766T3 - Kompozycje glikopirolanu i stearynianu magnezu w postaci suchego proszku - Google Patents

Kompozycje glikopirolanu i stearynianu magnezu w postaci suchego proszku

Info

Publication number
PL2422766T3
PL2422766T3 PL11190637T PL11190637T PL2422766T3 PL 2422766 T3 PL2422766 T3 PL 2422766T3 PL 11190637 T PL11190637 T PL 11190637T PL 11190637 T PL11190637 T PL 11190637T PL 2422766 T3 PL2422766 T3 PL 2422766T3
Authority
PL
Poland
Prior art keywords
glycopyrrolate
magnesium stearate
dry powder
powder compositions
compositions
Prior art date
Application number
PL11190637T
Other languages
English (en)
Inventor
David Morton
Martin Shott
Rebecca Davies
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32408337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2422766(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of PL2422766T3 publication Critical patent/PL2422766T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11190637T 2004-04-30 2005-04-29 Kompozycje glikopirolanu i stearynianu magnezu w postaci suchego proszku PL2422766T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0409703.6A GB0409703D0 (en) 2004-04-30 2004-04-30 Pharmaceutical compositions
EP11190637.6A EP2422766B1 (en) 2004-04-30 2005-04-29 Dry powder compositions of glycopyrrolate and magnesium stearate
EP05738040A EP1755555B1 (en) 2004-04-30 2005-04-29 Methods for preparing dry powder compositions of glycopyrrolate

Publications (1)

Publication Number Publication Date
PL2422766T3 true PL2422766T3 (pl) 2015-11-30

Family

ID=32408337

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11190637T PL2422766T3 (pl) 2004-04-30 2005-04-29 Kompozycje glikopirolanu i stearynianu magnezu w postaci suchego proszku
PL05738040T PL1755555T3 (pl) 2004-04-30 2005-04-29 Sposoby wytwarzania kompozycji w postaci suchego proszku z glikopirolanem

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL05738040T PL1755555T3 (pl) 2004-04-30 2005-04-29 Sposoby wytwarzania kompozycji w postaci suchego proszku z glikopirolanem

Country Status (27)

Country Link
US (1) US20080063719A1 (pl)
EP (3) EP1755555B1 (pl)
JP (2) JP5000483B2 (pl)
KR (1) KR101287919B1 (pl)
CN (3) CN102008453A (pl)
AU (2) AU2005237266B2 (pl)
BR (1) BRPI0510500B8 (pl)
CA (1) CA2563760C (pl)
CY (6) CY1113069T1 (pl)
DK (2) DK1755555T3 (pl)
ES (2) ES2546982T3 (pl)
GB (1) GB0409703D0 (pl)
HK (2) HK1095282A1 (pl)
HU (4) HUE025463T2 (pl)
IL (2) IL178651A (pl)
LT (1) LTC2422766I2 (pl)
LU (2) LU92176I2 (pl)
MX (2) MXPA06012493A (pl)
NO (1) NO20065502L (pl)
NZ (1) NZ550479A (pl)
PL (2) PL2422766T3 (pl)
PT (2) PT1755555E (pl)
RU (1) RU2396943C2 (pl)
SG (3) SG186673A1 (pl)
SI (2) SI2422766T1 (pl)
WO (1) WO2005105043A2 (pl)
ZA (1) ZA200609350B (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
CN101896162B (zh) * 2007-12-13 2013-06-05 诺瓦提斯公司 有机化合物
PL2229148T3 (pl) * 2007-12-13 2014-08-29 Novartis Ag Sposób otrzymywania krystalicznych cząstek stałych substancji leczniczej
EP3311820A1 (en) * 2008-02-26 2018-04-25 Sunovion Respiratory Development Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP3578169A1 (en) 2009-02-26 2019-12-11 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
AU2010238641A1 (en) * 2009-04-24 2011-11-10 Merck Sharp & Dohme Corp. Agglomerate formulations useful in dry powder inhalers
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
GB0921481D0 (en) * 2009-12-08 2010-01-20 Vectura Ltd Process and product
MX2012011179A (es) * 2010-03-31 2013-03-21 Glenmark Pharmaceuticals Ltd Composicion farmaceutica en polvo para inhalacion.
CA2794941C (en) 2010-04-01 2018-05-15 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
SI2560611T1 (en) 2010-04-21 2018-03-30 Chiesi Farmaceutici S.P.A. A process for preparing particles with reduced electrostatic charges
JP5792307B2 (ja) 2010-08-31 2015-10-07 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 水分制御特性を示す乾燥粉末吸入薬物製品及びその投与方法
JP5792308B2 (ja) 2010-08-31 2015-10-07 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 水分制御特性を示す乾燥粉末吸入薬物製品及びその投与方法
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
JP6267685B2 (ja) 2012-04-13 2018-01-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 集合粒子
AU2013100007B4 (en) * 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
CA2902795C (en) 2013-02-28 2021-06-15 Dermira, Inc. Glycopyrrolate salts
KR102391332B1 (ko) † 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
TN2017000077A1 (en) 2014-09-09 2018-07-04 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
AR102305A1 (es) 2014-10-16 2017-02-15 Teva Branded Pharmaceutical Products R&D Inc Procedimiento para preparar formulación farmacéutica inhalable de polvo seco
US9925168B2 (en) 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
CA3016488C (en) 2016-03-08 2023-04-11 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
JP6741773B2 (ja) 2016-03-08 2020-08-19 メレオ バイオファーマ １ リミテッド 炎症状態の急性増悪の治療のための投与レジメン
ES2805434T3 (es) 2016-07-29 2021-02-12 Inke Sa Procedimiento de estabilización de tamaño de partícula
US11219602B2 (en) 2017-03-15 2022-01-11 Vectura Limited Method for making a micronized dry powder formulation of glycopyrrolate and magnesium stearate
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
JP7280627B2 (ja) 2017-12-11 2023-05-24 メレオ バイオファーマ １ リミテッド 慢性閉塞性肺疾患の急性増悪の処置における３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの使用
HUE054266T2 (hu) 2017-12-11 2021-08-30 Mereo Biopharma 1 Ltd 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid alkalmazása krónikus obstruktív tüdõbetegség akut megjelenésének megelõzésében
KR20200078162A (ko) 2018-12-21 2020-07-01 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
WO2023117967A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
WO2023117985A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) * 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3709039A (en) * 1970-08-31 1973-01-09 Gen Time Corp Comfort humidity indicator
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
PT1283036E (pt) * 1998-11-13 2008-03-06 Jagotec Ag Inalador de pó seco de dose múltipla com um reservatório de pó
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US7744855B2 (en) 2000-06-27 2010-06-29 Vectura Limited Method of making particles for use in a pharmaceutical composition
EP2298279B1 (en) * 2000-11-30 2018-11-14 Vectura Limited Pharmaceutical compositions for inhalation
AU2002222118A1 (en) * 2000-11-30 2002-06-11 Vectura Limited Pharmaceutical compositions for inhalation
NZ528640A (en) * 2001-03-30 2004-06-25 Jagotec Ag Medical aerosol formulations
JP2005530765A (ja) * 2002-05-07 2005-10-13 ネクター セラピューティクス 乾燥粉末吸入器のためのカプセル及びそれを製造及び使用する方法
GB2405798A (en) * 2003-09-15 2005-03-16 Vectura Ltd Dry powder inhaler with primary and secondary piercing elements and a medicament pack for use with an inhalation device.
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
EP1861361A1 (en) * 2005-03-24 2007-12-05 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use

Also Published As

Publication number Publication date
BRPI0510500B1 (pt) 2019-04-24
CY2013012I1 (el) 2015-08-05
RU2006142322A (ru) 2008-06-20
EP1755555B1 (en) 2012-05-23
CN102008453A (zh) 2011-04-13
HUE025463T2 (en) 2016-02-29
CN1964700A (zh) 2007-05-16
SI1755555T1 (sl) 2012-10-30
US20080063719A1 (en) 2008-03-13
ES2388289T3 (es) 2012-10-11
EP2422766A2 (en) 2012-02-29
EP2422767A3 (en) 2012-04-25
CY2014015I2 (el) 2015-12-09
PT2422766E (pt) 2015-10-12
CY2014015I1 (el) 2015-12-09
PL1755555T3 (pl) 2012-11-30
DK1755555T3 (da) 2012-08-20
HUS1500072I1 (hu) 2016-02-29
CY2015060I1 (el) 2020-05-29
WO2005105043A2 (en) 2005-11-10
MX341426B (es) 2016-08-18
LU92392I2 (fr) 2015-11-02
EP2422767A2 (en) 2012-02-29
HUS1300006I1 (hu) 2016-07-28
SI2422766T1 (sl) 2015-10-30
CA2563760A1 (en) 2005-11-10
IL178651A (en) 2012-12-31
LU92176I2 (fr) 2013-05-27
AU2005237266A1 (en) 2005-11-10
CY2013012I2 (el) 2015-08-05
SG152292A1 (en) 2009-05-29
JP5000483B2 (ja) 2012-08-15
BRPI0510500B8 (pt) 2021-05-25
EP2422766B1 (en) 2015-06-24
IL178651A0 (en) 2007-02-11
CA2563760C (en) 2013-07-02
IL223545A0 (en) 2013-02-03
ES2546982T3 (es) 2015-09-30
AU2005237266B2 (en) 2010-11-11
HUS1500073I1 (hu) 2016-02-29
NO20065502L (no) 2007-01-24
RU2396943C2 (ru) 2010-08-20
AU2011200543A1 (en) 2011-03-03
EP2422766A3 (en) 2012-04-25
NZ550479A (en) 2009-11-27
WO2005105043A3 (en) 2006-05-04
SG10201605001SA (en) 2016-08-30
CN107252423A (zh) 2017-10-17
IL223545A (en) 2016-04-21
DK2422766T3 (da) 2015-08-31
KR101287919B1 (ko) 2013-07-18
HK1095282A1 (en) 2007-05-04
BRPI0510500A (pt) 2007-10-30
LTC2422766I2 (lt) 2020-02-10
MXPA06012493A (es) 2007-01-29
CY2015059I1 (el) 2020-05-29
AU2011200543B2 (en) 2012-11-29
JP2007535522A (ja) 2007-12-06
ZA200609350B (en) 2008-04-30
SG186673A1 (en) 2013-01-30
HK1167334A1 (en) 2012-11-30
CY1116655T1 (el) 2017-03-15
LU92176I9 (pl) 2019-01-04
KR20070033978A (ko) 2007-03-27
GB0409703D0 (en) 2004-06-02
AU2011200543A8 (en) 2011-03-31
JP2012031209A (ja) 2012-02-16
CY1113069T1 (el) 2015-08-05
PT1755555E (pt) 2012-08-17
JP5124718B2 (ja) 2013-01-23
EP1755555A2 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
HUS1500072I1 (hu) Glikopirrolát és magnézium-sztearát száraz por kompozíciói
EP1768926A4 (en) SILICURE COMPOSITIONS CONTAINING ALKALI METALS AND METHODS OF MAKING SAME
EP1851335A4 (en) COMPOSITIONS AND METHODS FOR USE OF STANDARDIZED MIXTURES
HK1155972A1 (zh) 羥甲基丁酸鹽組合物及其用途
EP1578403A4 (en) MODIFIED RELEASE MILNACIPRANE COMPOSITIONS
PT1888081T (pt) Composições contendo pufa e seus métodos de utilização
IL183017A0 (en) Stabilized ramipril compositions and methods of making
IL186490A0 (en) Multicyclic compounds and methods of their use
EP1931808A4 (en) METHODS AND COMPOSITIONS FOR POWDER METALLURGY
EP1827464A4 (en) ZINC COMPOSITIONS AND METHODS OF USE
EP1735456A4 (en) POYLMERIC COMPOSITIONS AND ASSOCIATED METHODS OF USE
ZA200606545B (en) Chronotherapeutic compositions and methods of their use
EP1767612A4 (en) SOLID FUEL COMPOSITION AND SOLID SOAP
PT1814977E (pt) Composições com base em arthrospira e suas utilizações
IL182126A (en) Preparations containing and used in the history of 5-phenoxyalkoxypsoralen
HK1109576A1 (en) Aequorin-containing compositions and methods of using same
EP1769007A4 (en) POLYMER COMPOSITIONS AND METHODS OF USE THEREOF
IL186606A0 (en) Compositions and uses of amooranin compounds
GB2423081B (en) Pro-fragrance and pro-flavorant compositions
ZA200707529B (en) Pro-fragrance and pro-flavorant compositions
GB0424051D0 (en) Compounds and compositions
GB0423292D0 (en) Compounds and compositions
GB0419260D0 (en) Skincare compositions and methods